A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies

Clinical trial NCT05822843 · COMPLETED

Trial details

NCT number: NCT05822843
Sponsor: Shanghai Escugen Biotechnology Co., Ltd
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

B-cell Lymphoid Malignancies

Start date: 2023-08-02
Primary completion: 2025-01-22
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.